Kröger K, Moerchel C, Moysidis Th, Santosa Frans, Incidence rate of pulmonary embolism in Germany: Data from the Federal Statistical Office. Journal of Thrombosis and thrombolysis, 29(3):349-53.

Wilkens, Heinrike, Held, Matthias Lungenembolie: Status 2018. Dtsch Arztebl Int 2021; 118: 618-2.

Silverstein MD, Heit JA, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ 3rd. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998;158(6):585–93.

Article  PubMed  Google Scholar 

Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrøm J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost. 2007;5(4):692–9.

Article  PubMed  Google Scholar 

Hojen AA, Nielsen PB, Overvad TF, Albertsen IE, Klok FA, Rolving N, et al. Long-term management of pulmonary embolism: a review of consequences, treatment, and rehabilitation. J Clin Med. 2022;11(19):5970.

Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165(10):1095–106.

Article  PubMed  Google Scholar 

Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis. 2011;31(3):326–43.

Article  PubMed  Google Scholar 

Hughes JE, Waldron C, Bennett KE, Cahir C. Prevalence of drug-drug interactions in older community-dwelling individuals: a systematic review and meta-analysis. Drugs Aging. 2023;40(2):117–34.

Article  PubMed  PubMed Central  Google Scholar 

Carollo M, Crisafulli S, Vitturi G, Besco M, Hinek D, Sartorio A, et al. Clinical impact of medication review and deprescribing in older inpatients: a systematic review and meta-analysis. J Am Geriatr Soc. 2024.:1-8

Mekaj YH, Mekaj AY, Duci SB, Miftari EI. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag. 2015;11:967–77.

Article  PubMed  PubMed Central  Google Scholar 

Egholm G, Olesen JS, Leinøe EB, Grove EL, Nielsen JD, Poulsen MH. Anticoagulation therapy for complex patient populations. Ugeskr Laeger. 2024;186(42):1-8.

Karetová D, Bultas J. Anticoagulant therapy in the elderly. Vnitr Lek. 2018;64(11):1011–20.

Article  PubMed  Google Scholar 

Capiau A, Mehuys E, Grymonprez M, Van Tongelen I, Christiaens T, Tommelein E, et al. Detection and management of clinically relevant drug-drug interactions with direct oral anticoagulants: an intervention study in community pharmacies. Thromb Res. 2024;238:223–31.

Article  PubMed  Google Scholar 

Meisinger C, Linseisen J, Kirchberger I, von Scheidt W, Berghaus TM. Long-term outcomes in patients with acute pulmonary embolism after in-hospital treatment: study protocol of the prospective Lungenembolie Augsburg Studie (LEA study). BMJ Open. 2019;9(10): e031411.

Article  PubMed  PubMed Central  Google Scholar 

Frey PM, Méan M, Limacher A, Leiss W, Schwab N, Rochat M, et al. Quality of life after pulmonary embolism: prospective validation of the German version of the PEmb-QoL questionnaire. Thromb Res. 2015;135(6):1087–92.

Article  PubMed  Google Scholar 

Martin P, Haefeli WE, Martin-Facklam M. A drug database model as a central element for computer-supported dose adjustment within a CPOE system. J Am Med Inform Assoc. 2004;11(5):427–32.

Article  PubMed  PubMed Central  Google Scholar 

Olakotan O, Mohd Yusof M, Ezat Wan Puteh S. A systematic review on CDSS alert appropriateness. Stud Health Technol Inform. 2020;270:906–10.

PubMed  Google Scholar 

Sutton RT, Pincock D, Baumgart DC, Sadowski DC, Fedorak RN, Kroeker KI. An overview of clinical decision support systems: benefits, risks, and strategies for success. NPJ Digit Med. 2020;3:17.

Article  PubMed  PubMed Central  Google Scholar 

Pauly A, Wolf C, Busse M, Strauß A-C, Krebs S, Dörje F, et al. Evaluation of eight drug interaction databases commonly used in the German healthcare system. Eur J Hosp Pharm. 2015;22(3):165–70.

Article  Google Scholar 

Elovic A, Pourmand A. Lexicomp app review. J Digit Imaging. 2020;33(1):17–20.

Article  PubMed  Google Scholar 

AWMF. S2k-Leitlinie Diagnostik und Therapie der Venenthrombose und Lungenembolie: Deutsche Gesellschaft für Angiologie - Gesellschaft für Gefäßmedizin e.V. (DGA); 2023 [medical guideline]. Available from: https://www.awmf.org/fachgesellschaften/deutsche-gesellschaft-fuer-angiologie-gesellschaft-fuer-gefaessmedizin-e-v-dga. [accessed 12.Dez 2024]

Wiggins BS, Saseen JJ, Page RL, Reed BN, Sneed K, Kostis JB, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2016;134(21):e468–95.

Article  PubMed  Google Scholar 

Niu J, Straubinger RM, Mager DE. Pharmacodynamic Drug-drug interactions. Clin Pharmacol Ther. 2019;105(6):1395–406.

Article  PubMed  Google Scholar 

Prescribing information Eliquis US Pfizer Inc. 2012 [Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202155s000lbl.pdf.] [accessed 22 Nov 2024]

Product Monograph Eliquis Pfizer Inc. Canada 2011 [updated 07.10.2019. Product Monograph]. Available from: https://webfiles.pfizer.com/file/89048fb0-de12-4e0d-b6fe-d1351e77108b?referrer=ccb731e5-4f2d-4f4a-b2dc-e5e912145fc6. [accessed 18 Nov 2024]

Company B-MS. Medication Guide Eliquis Apixaban 2015 [Available from: https://www.fda.gov/media/84985/download.] [accessed 21 Nov 2024]

Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.

Article  PubMed  Google Scholar 

Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365(8):699–708.

Article  PubMed  Google Scholar 

Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet. 2009;374(9683):29–38.

Article  PubMed  Google Scholar 

Davidson BL, Verheijen S, Lensing AW, Gebel M, Brighton TA, Lyons RM, et al. Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin. JAMA Intern Med. 2014;174(6):947–53.

Article  PubMed  Google Scholar 

Clarke A, Ibrahim A, Kiernan TJ. Triple antithrombotic therapy in patients with atrial fibrillation undergoing PCI: current evidence and practice. Expert Rev Cardiovasc Ther. 2018;16(10):715–23.

Article  PubMed  Google Scholar 

Mikus G, Foerster KI, Schaumaeker M, Lehmann ML, Burhenne J, Haefeli WE. Application of a microdosed cocktail of 3 oral factor Xa inhibitors to study drug-drug interactions with different perpetrator drugs. Br J Clin Pharmacol. 2020;86(8):1632–41.

Article  PubMed  PubMed Central  Google Scholar 

Rohr BS, Krohmer E, Foerster KI, Burhenne J, Schulz M, Blank A, et al. Time course of the interaction between oral short-term ritonavir therapy with three factor Xa inhibitors and the activity of CYP2D6, CYP2C19, and CYP3A4 in healthy volunteers. Clin Pharmacokinet. 2024;63(4):469–81.

Article  PubMed  PubMed Central  Google Scholar 

Rohr BS, Foerster KI, Blank A, Burhenne J, Mahmoudi M, Haefeli WE, et al. Perpetrator characteristics of azole antifungal drugs on three oral factor Xa inhibitors administered as a microdosed cocktail. Clin Pharmacokinet. 2022;61(1):97–109.

Article  PubMed  Google Scholar 

Product Monograph Rivaroxaban Xarelto Canada 2018 [Available from: https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92592.] [accessed 10.11.2024]

Prescribing Information Xarelto Janssen Pharmaceuticals Inc US 2015 [Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022406s012lbl.pdf.] [accessed 20 Oct 2024]

Kubitza D, Becka M, Mueck W, Zuehlsdorf M. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban–an oral, direct factor Xa inhibitor–are not affected by aspirin. J Clin Pharmacol. 2006;46(9):981–90.

Article  PubMed  Google Scholar 

Risselada AJ, Visser MJ, van Roon E. Pulmonary embolism due to interaction between rivaroxaban and carbamazepine. Ned Tijdschr Geneeskd. 2013;157(52):A6568.

PubMed  Google Scholar 

Sennesael AL, Larock AS, Hainaut P, Lessire S, Hardy M, Douxfils J, et al. The Impact of Strong Inducers on Direct Oral Anticoagulant Levels. Am J Med. 2021;134(10):1295–9.

Article  PubMed  Google Scholar 

Gronich N, Stein N, Muszkat M. Association between use of pharmacokinetic-interacting drugs and effectiveness and safety of direct acting oral anticoagulants: nested case-control study. Clin Pharmacol Ther. 2021;110(6):1526–36.

Article  PubMed  PubMed Central  Google Scholar 

Mendell J, Zahir H, Matsushima N, Noveck R, Lee F, Chen S, et al. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs. 2013;13(5):331–42.

Article  PubMed  PubMed Central  Google Scholar 

Vazquez SR. Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions. Blood. 2018;132(21):2230–9.

Art